Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
CAR T-cell therapy
|
| gptkbp:administrativeDivision |
single infusion
|
| gptkbp:approves |
treatment of large B-cell lymphoma
|
| gptkbp:availability |
limited to specialized centers
|
| gptkbp:careInstructions |
assessed by imaging
|
| gptkbp:clinicalTrials |
Phase 2
updated regularly high response rates published in medical journals monitored in trials included in treatment protocols ZUMA-7 access and affordability evaluated in follow-up studies ongoing for various indications |
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:contraindication |
reported in clinical studies
|
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:diseaseResistance |
gptkb:non-Hodgkin_lymphoma
T-cell activation |
| gptkbp:dosageForm |
infusion
|
| gptkbp:hasCapacity |
available through healthcare providers
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
specific criteria
analyzed in economic studies based on biomarkers provided by healthcare teams |
| gptkbp:historicalResearch |
focused on combination therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lisocabtagene maraleucel
|
| gptkbp:impact |
variable
standardized procedures immunotherapy potentially curative restricted to certain hospitals |
| gptkbp:mandates |
relapsed or refractory B-cell malignancies
|
| gptkbp:marketedAs |
Breyanzi
|
| gptkbp:offers |
high
|
| gptkbp:origin |
derived from patient's own T-cells
|
| gptkbp:patentType |
February 2021
|
| gptkbp:postRetirementCareer |
required
|
| gptkbp:productionCompany |
ex vivo expansion
|
| gptkbp:regulatoryCompliance |
orphan_drug_designation
|
| gptkbp:research |
supported by grants
|
| gptkbp:researchFocus |
hematologic malignancies
|
| gptkbp:researchInterest |
numerous studies published
multiple clinical sites |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
monitored in clinical settings
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:storage |
frozen
|
| gptkbp:targets |
CD19
|
| gptkbp:triggerType |
genetically modifies T-cells
|
| gptkbp:type |
autologous T-cell therapy
|